Investigating the role of Fbw7 in cancer and cell growth regulation
Official title: The Fbw7 ubiquitin ligase network: normal and neoplastic functions
Funded at Fred Hutchinson Cancer Center · NIH-11079455 · Data updated 2026-11-12
This study is looking at a protein called Fbw7 that helps control other proteins related to cell growth and cancer, to see how it works with a cancer-related protein called c-Myc, which could help us find new ways to treat different types of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $496,612 |
| NIH project number | 5R01CA280280-03 |
| Project ID | NIH-11079455 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers associated with c-Myc dysregulation or mutations in the Fbw7 gene.
✕Less likely to help
Patients with cancers unrelated to the Fbw7 pathway or those without c-Myc involvement may not benefit from this research.
What this research studies
This research explores the Fbw7 protein, which plays a critical role in regulating other proteins involved in cell growth and cancer development. By understanding how Fbw7 interacts with its substrates, particularly the oncogenic protein c-Myc, the research aims to uncover mechanisms that lead to cancer progression. The study will investigate how Fbw7 controls the stability and activity of Myc in both healthy and cancerous cells, as well as how mutations in Fbw7 can contribute to tumor formation. This could lead to new therapeutic strategies for treating various cancers.
Why it matters
Potential benefit: If successful, this research could lead to innovative cancer therapies that target the Fbw7 pathway, potentially improving treatment outcomes for patients with cancers driven by c-Myc and other oncoproteins.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer biology, indicating that this approach could yield significant advancements.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Clurman, Bruce E — Fred Hutchinson Cancer Center
- Study coordinator: Clurman, Bruce E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.